The American Cancer Society now recommends routine prostate cancer screening with a PSA test, reversing its 2010 guidance, which made no universal recommendation. The new guidelines were released Thursday.
Men at average risk should get a PSA test every two years from age 50 to 69. Men at higher risk, based on race and family history, should start at 45. The ACS recommends yearly testing for all Black men starting at 45. Non-Black men should also test yearly from 45 if a close relative was diagnosed before age 65, or if more than one relative has had the disease. If only one close relative was diagnosed at 65 or older, non-Black men should test every two years starting at 45.
Men aged 70 to 74 should discuss continuing screening with their doctor. The ACS does not recommend screening for men 75 and older.
The ACS says the update reflects new evidence since 2010 showing that screening saves lives. It also says improved case management can avoid harms from overdiagnosis and overtreatment. The organization notes that many men with prostate cancer will never have their cancer grow or cause harm during their lifetime, while treatment can cause erectile dysfunction and urinary incontinence.
The guidance adds safeguards. All men should be informed about the risks and benefits of screening. A PSA result of 3 ng/mL or higher for men under 70, or 6.5 ng/mL or higher for men 70 and older, should be repeated before further steps. If the repeat remains high, the ACS recommends a prostate MRI or a validated biomarker test. A biopsy should follow only if cancer is strongly suspected, such as with a very high PSA result. For men diagnosed with low-risk cancer, the ACS recommends active surveillance as the initial approach.
Dr. Shanthi Sivendran, interim chief patient officer for the ACS, said in a statement: "By catching aggressive cancers with a simple PSA blood test, you open the door to highly effective treatments that protect your future." She added that "lower-risk findings can be safely managed through careful, active surveillance."
The source reports that the US Preventive Services Task Force, a federal panel, is working on its own update. The source also reports that the panel was recently overhauled by Health Secretary Robert F. Kennedy Jr., and that reportedly some new members have conflicts of interest.
The source estimates that nearly 334,000 men will be diagnosed with prostate cancer in 2026 and that over 36,320 will die from the disease. It describes prostate cancer as the second leading cause of cancer death in US men.